Jeff Settleman
Dartmouth–Hitchcock Medical Center, Center for Cancer Research
Papers
2
Total Citations
105
H-Index
2
About
Jeff Settleman has made transformative contributions to cancer biology and precision oncology, with a career centered on understanding how genetic alterations drive tumor growth and drug response. His key research areas include targeted cancer therapies, mechanisms of drug resistance, and the development of clinically relevant genomic biomarkers. Settleman is widely recognized for pioneering work that links specific oncogenic mutations—such as those in EGFR and KRAS—to therapeutic vulnerabilities, helping to shape the paradigm of genotype-directed cancer treatment. Among his notable achievements, he led studies revealing that targeting the cyclin E-Cdk-2 complex in lung cancer triggers anaphase catastrophe, offering a novel therapeutic strategy for tumors with deregulated cell cycle control. He also advanced drug screening platforms that integrate large, annotated cancer cell line panels to identify molecular targeted radiosensitizers and match them with predictive genomic biomarkers. With hundreds of highly cited publications and a sustained influence on both basic and translational research, Settleman’s work has directly informed clinical trial design and the development of rational combination therapies. His contributions continue to guide how researchers and clinicians approach the molecular heterogeneity of cancer and the pursuit of more effective, personalized treatments.
Research Focus
Key Achievements
Top Papers
- 1
- 2